Is Hyaluronic acid + Lidocaine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Hyaluronic acid + Lidocaine, including TEOSYAL PureSence ULTRA DEEP (25,0.3 mg/ml,%, Gel for injection, SAR 725.05); TEOSYAL PureSense REDENSITY 2 (15,0.3 mg/ml,%, Gel for injection, SAR 418.60); TEOSYAL PureSense ULTIMATE (22,0.3 mg/ml,%, Gel for injection, SAR 531.70); Teosyal PureSense KISS (25,0.3 mg/ml,%, Gel for injection, SAR 707.85).

Active substances

Hyaluronic acid + Lidocaine

SFDA 8

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
TEOSYAL PureSence ULTRA DEEP	25,0.3 mg/ml,%	Gel for injection · Subcutaneous use	2 Pre-filled syringe	SAR 725.05	Generic · Prescription	TeoxaneSA	Valid
TEOSYAL PureSense REDENSITY 2	15,0.3 mg/ml,%	Gel for injection · Intradermal use	2 Pre-filled syringe	SAR 418.60	Generic · Prescription	TeoxaneSA	Valid
TEOSYAL PureSense ULTIMATE	22,0.3 mg/ml,%	Gel for injection · Subcutaneous use	2 Pre-filled syringe	SAR 531.70	Generic · Prescription	TeoxaneSA	Valid
Teosyal PureSense KISS	25,0.3 mg/ml,%	Gel for injection · Intradermal use	2 Pre-filled syringe	SAR 707.85	Generic · Prescription	TeoxaneSA	Valid
JUVEDERM ULTRA 4	24, 3 mg/g	Gel · Intradermal use	2 Pre-filled syringe	SAR 763.55	Generic · Prescription	ALLERGAN	Withdrawn by MAH · Not Marketed
JUVEDERM VOLBELLA WITH LIDOCAINE	15, 3 mg/g	Gel · Intradermal use	2 Pre-filled syringe	SAR 1136.95	Generic · Prescription	ALLERGAN	Withdrawn by MAH · Not Marketed
JUVEDERM VOLIFT WITH LIDOCAINE	17.5, 3 mg/g	Gel · Intradermal use	2 Pre-filled syringe	SAR 1192.90	Generic · Prescription	ALLERGAN	Withdrawn by MAH · Not Marketed
JUVEDERM VOLUMA WITH LIDOCAINE	20, 3 mg/g	Gel · Intradermal use	2 Pre-filled syringe	SAR 1190.75	Generic · Prescription	ALLERGAN	Withdrawn by MAH · Not Marketed

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.